JHS Svendgaard Laboratories Limited has announced the reopening of a special window to facilitate the re-lodgement of transfer requests for physical shares, providing shareholders with a crucial opportunity to complete previously incomplete transactions.

Special Window Details

The company has informed all shareholders about the availability of this special facility following SEBI circular No. SEBI/HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026. The window will remain open for a period of one year, providing ample time for shareholders to complete their transfer processes.

Eligibility and Scope

The special window covers transfer requests that were submitted earlier but were rejected, returned, or not attended to due to various reasons. This includes cases where there were deficiencies in documents, processes, or other issues that prevented the completion of share transfers.

Shareholders who wish to avail this opportunity can contact the company's designated Share Transfer Agent for assistance with the re-lodgement process.

Contact Information

For shareholders seeking to utilize this facility, the company has provided specific contact details:

Company Information Updates

The company has updated its official website at www.svendgaard.com with comprehensive details regarding the opening of this special window. Shareholders are encouraged to visit the website for additional information and guidance on the re-lodgement process.

Regulatory Compliance

This initiative demonstrates JHS Svendgaard Laboratories Limited's commitment to regulatory compliance and shareholder service. The company has issued this notice in accordance with Regulation 30 read with Part A of Schedule III of the SEBI (LODR) Regulations, 2015, ensuring full transparency and proper communication with stakeholders.

The announcement was signed by Komal Jha, Company Secretary & Compliance Officer, and has been communicated to both BSE Limited and National Stock Exchange of India Limited as per regulatory requirements.

JHS Svendgaard Laboratories Limited has submitted its quarterly compliance report under SEBI regulations, confirming no deviation in the utilization of funds raised through preferential issue for the quarter ended December 31, 2025. The statement was approved by the Board of Directors at their meeting held on February 10, 2026.

Fund Raising Details

The company had raised Rs. 29.99 crores through preferential issue on June 4, 2024. The fund utilization report was filed pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates quarterly disclosure of fund utilization by listed entities.

Fund Allocation and Utilization

The company has modified its original fund allocation objectives, with shareholder approval obtained on July 4, 2024. The revised allocation demonstrates strategic reallocation of resources across different business priorities.

Strategic Reallocation

The most significant change in fund allocation involves the reduction of the original Jammu & Kashmir project allocation from Rs. 2249.99 lakhs to Rs. 599.99 lakhs. This project was initially planned for setting up a new manufacturing facility under the Industrial Development Scheme (IDS) 2021-2030 in Jammu & Kashmir, but has been modified to focus specifically on acquiring equipment for the manufacturing facility.

A new allocation of Rs. 1650.00 lakhs has been created for strategic fund infusion in the group entity JHS Svendgaard Retail Ventures Ltd., aimed at funding expansion plans. Out of this allocation, Rs. 112.50 lakhs has been utilized during the reporting quarter.

Compliance and Oversight

The company reported no comments from the Audit Committee or auditors regarding the fund utilization. The statement confirms that no monitoring agency oversight is applicable for this fund raising. The quarterly report demonstrates the company's adherence to regulatory disclosure requirements and transparent fund management practices.